Treatment Advances in Graft-Vs-Host Disease: A 48-Year-Old Man With Chronic Graft-Vs-Host Disease

home / case-based-peer-perspectives / treatment-advances-in-graft-versus-host-disease-a-48-year-old-man-with-chronic-graft-versus-host

Nelson Chao, MD, MBA,discusses how effective management of GVHD requires comprehensive assessment of symptoms across multiple organ systems, strategic use of steroid therapy as first-line treatment with appropriate supportive care measures, timely recognition of steroid-refractory disease warranting JAK inhibition with ruxolitinib or other emerging therapies as supported by clinical trials like REACH3, vigilant monitoring of treatment-related adverse events through structured protocols, thorough patient education regarding treatment expectations, and a multidisciplinary approach to optimize both disease control and quality of life in transplant survivors.

1 expert is featured in this series.

EP. 1: Clinical Case – A Patient With Steroid-Refractory cGVHD

Nelson Chao, MD, MBA
March 31st 2025

A panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting multiple organ systems, including the skin (rash, itching), gastrointestinal tract (diarrhea, nausea, abdominal pain), liver (elevated enzymes, jaundice), and lungs (shortness of breath, cough), with severity assessment typically following established criteria.

Watch